371 related articles for article (PubMed ID: 33597521)
1. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
[TBL] [Abstract][Full Text] [Related]
2. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
Swanstrom JA; Nivarthi UK; Patel B; Delacruz MJ; Yount B; Widman DG; Durbin AP; Whitehead SS; De Silva AM; Baric RS
J Infect Dis; 2019 Jun; 220(2):219-227. PubMed ID: 30895307
[TBL] [Abstract][Full Text] [Related]
3. Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.
Henein S; Adams C; Bonaparte M; Moser JM; Munteanu A; Baric R; de Silva AM
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34003796
[TBL] [Abstract][Full Text] [Related]
4. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
5. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
Swanstrom JA; Henein S; Plante JA; Yount BL; Widman DG; Gallichotte EN; Dean HJ; Osorio JE; Partidos CD; de Silva AM; Baric RS
J Infect Dis; 2018 May; 217(12):1932-1941. PubMed ID: 29800370
[TBL] [Abstract][Full Text] [Related]
6. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
8. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
9. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
10. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003.
Tu HA; Nivarthi UK; Graham NR; Eisenhauer P; Delacruz MJ; Pierce KK; Whitehead SS; Boyson JE; Botten JW; Kirkpatrick BD; Durbin AP; deSilva AM; Diehl SA
Cell Rep Med; 2020 Dec; 1(9):100155. PubMed ID: 33377126
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
Kallas EG; Precioso AR; Palacios R; Thomé B; Braga PE; Vanni T; Campos LMA; Ferrari L; Mondini G; da Graça Salomão M; da Silva A; Espinola HM; do Prado Santos J; Santos CLS; Timenetsky MDCST; Miraglia JL; Gallina NMF; Weiskopf D; Sette A; Goulart R; Salles RT; Maestri A; Sallum AME; Farhat SCL; Sakita NK; Ferreira JCOA; Silveira CGT; Costa PR; Raw I; Whitehead SS; Durbin AP; Kalil J
Lancet Infect Dis; 2020 Jul; 20(7):839-850. PubMed ID: 32220283
[TBL] [Abstract][Full Text] [Related]
13. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
[TBL] [Abstract][Full Text] [Related]
14. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
White LJ; Young EF; Stoops MJ; Henein SR; Adams EC; Baric RS; de Silva AM
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009258. PubMed ID: 33711074
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
[TBL] [Abstract][Full Text] [Related]
16. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Whitehead SS
Expert Rev Vaccines; 2016; 15(4):509-17. PubMed ID: 26559731
[TBL] [Abstract][Full Text] [Related]
17. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.
Messer WB; de Alwis R; Yount BL; Royal SR; Huynh JP; Smith SA; Crowe JE; Doranz BJ; Kahle KM; Pfaff JM; White LJ; Sariol CA; de Silva AM; Baric RS
Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1939-44. PubMed ID: 24385585
[TBL] [Abstract][Full Text] [Related]
18. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
J Virol; 2021 May; 95(12):. PubMed ID: 33762420
[TBL] [Abstract][Full Text] [Related]
19. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
[TBL] [Abstract][Full Text] [Related]
20. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
